Raymond DuBois to Colonic Neoplasms
This is a "connection" page, showing publications Raymond DuBois has written about Colonic Neoplasms.
Connection Strength
1.324
-
Metronomic topotecan for colorectal cancer: a promising new option. Gut. 2013 Feb; 62(2):190-1.
Score: 0.343
-
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 2008 Nov 15; 68(22):9331-7.
Score: 0.268
-
15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat. 2004 Jan; 73(1-2):111-22.
Score: 0.191
-
Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem. 2003 Jun 20; 278(25):22669-77.
Score: 0.180
-
COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002; 42:55-80.
Score: 0.167
-
Tailoring treatment in translational cancer research: An Interview with Raymond N. DuBois, MD, PhD. Interviewed by Elaine Musgrave. Clin Transl Sci. 2009 Jun; 2(3):178-9.
Score: 0.070
-
Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer. 2006 Nov 17; 5:63.
Score: 0.058
-
Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging. Mol Imaging Biol. 2003 Sep-Oct; 5(5):286-303.
Score: 0.047